BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 23526739)

  • 1. PAX-FOXO1 fusion status drives unfavorable outcome for children with rhabdomyosarcoma: a children's oncology group report.
    Skapek SX; Anderson J; Barr FG; Bridge JA; Gastier-Foster JM; Parham DM; Rudzinski ER; Triche T; Hawkins DS
    Pediatr Blood Cancer; 2013 Sep; 60(9):1411-7. PubMed ID: 23526739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion gene-negative alveolar rhabdomyosarcoma is clinically and molecularly indistinguishable from embryonal rhabdomyosarcoma.
    Williamson D; Missiaglia E; de Reyniès A; Pierron G; Thuille B; Palenzuela G; Thway K; Orbach D; Laé M; Fréneaux P; Pritchard-Jones K; Oberlin O; Shipley J; Delattre O
    J Clin Oncol; 2010 May; 28(13):2151-8. PubMed ID: 20351326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dense pattern of embryonal rhabdomyosarcoma, a lesion easily confused with alveolar rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Rudzinski ER; Teot LA; Anderson JR; Moore J; Bridge JA; Barr FG; Gastier-Foster JM; Skapek SX; Hawkins DS; Parham DM
    Am J Clin Pathol; 2013 Jul; 140(1):82-90. PubMed ID: 23765537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global gene expression profiling of PAX-FKHR fusion-positive alveolar and PAX-FKHR fusion-negative embryonal rhabdomyosarcomas.
    Laé M; Ahn EH; Mercado GE; Chuai S; Edgar M; Pawel BR; Olshen A; Barr FG; Ladanyi M
    J Pathol; 2007 Jun; 212(2):143-51. PubMed ID: 17471488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histology, Fusion Status, and Outcome in Alveolar Rhabdomyosarcoma With Low-Risk Clinical Features: A Report From the Children's Oncology Group.
    Arnold MA; Anderson JR; Gastier-Foster JM; Barr FG; Skapek SX; Hawkins DS; Raney RB; Parham DM; Teot LA; Rudzinski ER; Walterhouse DO
    Pediatr Blood Cancer; 2016 Apr; 63(4):634-9. PubMed ID: 26756883
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology Group.
    Hingorani P; Missiaglia E; Shipley J; Anderson JR; Triche TJ; Delorenzi M; Gastier-Foster J; Wing M; Hawkins DS; Skapek SX
    Clin Cancer Res; 2015 Oct; 21(20):4733-9. PubMed ID: 26473193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histology, fusion status, and outcome in metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
    Rudzinski ER; Anderson JR; Chi YY; Gastier-Foster JM; Astbury C; Barr FG; Skapek SX; Hawkins DS; Weigel BJ; Pappo A; Meyer WH; Arnold MA; Teot LA; Parham DM
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28521080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PAX-FOXO1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
    Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
    Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Classification of rhabdomyosarcoma and its molecular basis.
    Parham DM; Barr FG
    Adv Anat Pathol; 2013 Nov; 20(6):387-97. PubMed ID: 24113309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
    Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
    Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of target genes of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Ahn EH; Mercado GE; Laé M; Ladanyi M
    Oncol Rep; 2013 Aug; 30(2):968-78. PubMed ID: 23733015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
    Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
    Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myogenin, AP2β, NOS-1, and HMGA2 are surrogate markers of fusion status in rhabdomyosarcoma: a report from the soft tissue sarcoma committee of the children's oncology group.
    Rudzinski ER; Anderson JR; Lyden ER; Bridge JA; Barr FG; Gastier-Foster JM; Bachmeyer K; Skapek SX; Hawkins DS; Teot LA; Parham DM
    Am J Surg Pathol; 2014 May; 38(5):654-9. PubMed ID: 24618610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rhabdomyosarcoma: value of myogenin expression analysis and molecular testing in diagnosing the alveolar subtype: an analysis of 109 paraffin-embedded specimens.
    Hostein I; Andraud-Fregeville M; Guillou L; Terrier-Lacombe MJ; Deminière C; Ranchère D; Lussan C; Longavenne E; Bui NB; Delattre O; Coindre JM
    Cancer; 2004 Dec; 101(12):2817-24. PubMed ID: 15536621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between histology and PAX/FKHR fusion status in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
    Parham DM; Qualman SJ; Teot L; Barr FG; Morotti R; Sorensen PH; Triche TJ; Meyer WH;
    Am J Surg Pathol; 2007 Jun; 31(6):895-901. PubMed ID: 17527077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PAX3/FOXO1 fusion gene status is the key prognostic molecular marker in rhabdomyosarcoma and significantly improves current risk stratification.
    Missiaglia E; Williamson D; Chisholm J; Wirapati P; Pierron G; Petel F; Concordet JP; Thway K; Oberlin O; Pritchard-Jones K; Delattre O; Delorenzi M; Shipley J
    J Clin Oncol; 2012 May; 30(14):1670-7. PubMed ID: 22454413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee.
    Butel T; Karanian M; Pierron G; Orbach D; Ranchere D; Cozic N; Galmiche L; Coulomb A; Corradini N; Lacour B; Proust S; Guerin F; Boutroux H; Rome A; Mansuy L; Vérité C; Defachelles AS; Tirode F; Minard-Colin V
    Cancer Med; 2020 Apr; 9(8):2698-2709. PubMed ID: 32087612
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic and clinical analysis of fusion gene amplification in rhabdomyosarcoma: a report from the Children's Oncology Group.
    Duan F; Smith LM; Gustafson DM; Zhang C; Dunlevy MJ; Gastier-Foster JM; Barr FG
    Genes Chromosomes Cancer; 2012 Jul; 51(7):662-74. PubMed ID: 22447499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.